Senate places Expedited Access to Biosimilars Act on legislative calendar
/ 1 min read
Table of Contents
The Senate has placed a new bill, called the Expedited Access to Biosimilars Act, on its legislative calendar. This means the bill is ready for potential consideration or debate by the Senate.
Why it matters: This is a legislative proposal intended to speed up the regulatory process for specific types of medicine; its impact depends entirely on whether it passes both chambers and is signed into law.
Who it affects
- Pharmaceutical companies that develop biological drugs and biosimilars
This information comes from Congress.gov regarding a Senate bill; readers should consult the official text for full details before relying on it.
Agency: Senate
Source: Congress.gov — read the official document